Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 8, 2017
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
[ Tue, Aug 08th 2017
] - WOPRAI
Mon, August 7, 2017
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
[ Mon, Aug 07th 2017
] - WOPRAI
Matthew Harrison Maintained (BLUE) at Hold with Increased Target to $105 on, Aug 7th, 2017
Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Hold with Increased Target from $103 to $105 on, Aug 7th, 2017.
Matthew has made no other calls on BLUE in the last 4 months.
There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Vincent Chen of "Bernstein" Initiated at Hold and Held Target at $109 on, Thursday, July 27th, 2017
- Dane Leone of "BTIG" Downgraded from Strong Buy to Hold on, Friday, June 30th, 2017
This is the rating of the analyst that currently disagrees with Matthew
- Matthew Luchini of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $108 on, Tuesday, June 6th, 2017
